Allogene therapeutics inc ALLO.US 總覽分析
ALLO 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
ALLO 近期報酬表現
0.86%
Allogene therapeutics inc
4.57%
同產業平均
3.26%
S&P500
與 ALLO 同產業的標的表現
- NTLA Intellia therapeutics inc價值 4 分趨勢 3 分波段 5 分籌碼 3 分股利 1 分查看更多
ALLO 公司資訊
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.